Would you consider stopping EGFR inhibitor in EGFR mutant NSCLC on a patient who was NED for >5 years?

It's a great question! My bias would be to lean toward continuation in the absence of significant impact on QOL. Some literature is available describing the experience of long-term responders, but even then, the definition of long-term responders is up about 2-3 years, so well below the duration of ...